Using this method, this study compared the differences in LCFA metabolism between healthy individuals and psoriasis patients and examined the changes in LCFAs in each psoriasis patient receiving pretherapy and posttreatment with anti-IL-17A mAb. The gene discussed is IL17A; the disease is psoriasis.